Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) today announced the first participant in Italy has been dosed in the Company’s Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder.
JMP Securities Reiterates Market Outperform on Uber Technologies, Maintains $55 Price Target
JMP Securities analyst Andrew Boone reiterates Uber Technologies (NYSE:UBER) with a Market Outperform and maintains $55 price target.
